Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission.
暂无分享,去创建一个
L. Dagna | R. Caporali | R. Priori | C. Montecucco | F. Ciccia | R. Giacomelli | M. Govoni | F. Iannone | L. Cantarini | P. Ruscitti | S. Colafrancesco | P. Sfriso | G. Pappagallo | P. Leccese | G. Pistone
[1] C. Campochiaro,et al. Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry , 2022, Frontiers in Medicine.
[2] R. Giacomelli,et al. Systematic review on the use of biologics in adult-onset still's disease. , 2022, Seminars in arthritis and rheumatism.
[3] A. Burlui,et al. Adult-Onset Still’s Disease—A Complex Disease, a Challenging Treatment , 2022, International journal of molecular sciences.
[4] Q. Lu,et al. Adult-onset Still’s disease: A disease at the crossroad of innate immunity and autoimmunity , 2022, Frontiers in Medicine.
[5] Liangjing Lu,et al. Clinical phenotypes and prognostic factors of adult-onset Still’s disease: data from a large inpatient cohort , 2021, Arthritis Research & Therapy.
[6] T. Hosoya,et al. Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still’s disease , 2021, Arthritis Research & Therapy.
[7] A. Tomelleri,et al. Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease. , 2021, Clinical and experimental rheumatology.
[8] S. Çolak,et al. Biological treatment in resistant adult-onset Still’s disease: A single-center, retrospective cohort study , 2021, Archives of rheumatology.
[9] D. Foell,et al. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease , 2021, Arthritis Research & Therapy.
[10] P. Sfikakis,et al. Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. , 2020, Seminars in arthritis and rheumatism.
[11] A. Tomelleri,et al. Drug retention rates of biological agents in adult onset Still's disease. , 2020, Seminars in arthritis and rheumatism.
[12] C. Campochiaro,et al. Current treatment options and safety considerations when treating adult-onset Still’s disease , 2020, Expert opinion on drug safety.
[13] A. Vitale,et al. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease , 2020, Mediators of inflammation.
[14] C. Wouters,et al. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study , 2020, Arthritis & rheumatology.
[15] F. Atzeni,et al. Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients , 2020, Arthritis Research & Therapy.
[16] B. Anić,et al. Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review , 2020, Rheumatology International.
[17] G. Bertsias,et al. AB1041 BIOLOGICS IN ADULT’S ONSET STILL’S DISEASE: TREATMENT STRATEGIES AND SAFETY IN SINGLE CENTER COHORT WITH LONG-TERM FOLLOW-UP , 2020, Annals of the Rheumatic Diseases.
[18] A. Tomelleri,et al. FRI0506 EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILL’S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE , 2020, Annals of the Rheumatic Diseases.
[19] L. Sammut,et al. EP18 Use of anakinra for haemophagocytic lymphohistiocytosis in adults , 2020 .
[20] G. Cavalli,et al. Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes , 2020, Frontiers in Medicine.
[21] I. Yokota,et al. Calcineurin inhibitors for adult-onset Still's disease: a multicentre retrospective cohort study. , 2020, Clinical and experimental rheumatology.
[22] L. Dagna,et al. Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts , 2019, Arthritis Research & Therapy.
[23] F. Atzeni,et al. Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort , 2019, Rheumatology International.
[24] D. Foell,et al. Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study , 2019, Arthritis & rheumatology.
[25] G. Cavalli,et al. Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response , 2019, Front. Pharmacol..
[26] G. Guggino,et al. Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study , 2019, Medicine.
[27] T. Barnetche,et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy , 2019, Arthritis Research & Therapy.
[28] E. Feist,et al. Mechanisms, biomarkers and targets for adult-onset Still’s disease , 2018, Nature Reviews Rheumatology.
[29] Y. Shoenfeld,et al. A comprehensive review on adult onset Still's disease. , 2018, Journal of autoimmunity.
[30] N. Okiyama,et al. Evidence-based clinical practice guideline for adult Still’s disease , 2018, Modern rheumatology.
[31] H. Fang,et al. Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review , 2018, Therapeutics and clinical risk management.
[32] D. Rossi,et al. How I treat patients with adult onset Still's disease in clinical practice. , 2017, Autoimmunity reviews.
[33] G. De Sarro,et al. Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies , 2017, Expert review of clinical immunology.
[34] L. Punzi,et al. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study , 2017, Front. Pharmacol..
[35] K. Amano,et al. THU0577 Tocilizumab monotherapy for adult onset still's disease – results of 52-week treatment of a prospective, single-center, single-arm, open trial , 2017 .
[36] G. Ferraccioli,et al. Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis , 2017, Medicine.
[37] M. Valenti,et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers , 2016, BMC Medicine.
[38] H. Kato,et al. Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra , 2016, Case reports in rheumatology.
[39] M. Inanç,et al. FRI0502 Biologic Agents in Refractory Adult Still's Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab , 2016 .
[40] Q. Yao,et al. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature. , 2016, Seminars in arthritis and rheumatism.
[41] S. Bombardieri,et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients , 2016, Clinical Rheumatology.
[42] D. Solmaz,et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. , 2016, Journal of autoimmunity.
[43] F. Vandergheynst,et al. Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still's Disease. , 2016, Acta medica.
[44] C. Campochiaro,et al. Efficacy and safety of biological agents in adult-onset Still’s disease , 2015, Scandinavian journal of rheumatology.
[45] S. Castañeda,et al. SAT0525 Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still's Disease. Multicenter Study of 75 Patients , 2015 .
[46] P. Sève,et al. Adult-onset Still's disease. , 2014, Autoimmunity reviews.
[47] S. Castañeda,et al. THU0390 Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Open-Label Study of 34 Patients , 2014 .
[48] J. Ablin,et al. Tocilizumab in Adult-onset Still’s Disease: the Israeli Experience , 2014, The Journal of Rheumatology.
[49] P. Efthimiou,et al. THU0401 Successful use of canakinumab in adult-onset still’s disease refractory to short acting IL-1 inhibitors , 2013 .
[50] Z. Amoura,et al. Anakinra in Adult‐Onset Still's Disease: Long‐Term Treatment in Patients Resistant to Conventional Therapy , 2013, Arthritis care & research.
[51] C. Suh,et al. Therapeutic responses and prognosis in adult-onset Still’s disease , 2012, Rheumatology International.
[52] J. Nolla,et al. Adult onset Still's disease: review of 41 cases. , 2011, Clinical and experimental rheumatology.
[53] E. Baldissera,et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. , 2010, Arthritis and rheumatism.
[54] Chengde Yang,et al. Clinical Features and Prognosis of Adult-onset Still’s Disease: 61 Cases from China , 2009, The Journal of Rheumatology.
[55] H. Inoue,et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease , 2009, Modern rheumatology.
[56] J. Sibilia,et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France , 2007, Annals of the rheumatic diseases.
[57] V. Joshi,et al. Adult onset Still’s disease: a study of 14 cases , 2007, Clinical Rheumatology.
[58] M. Boers,et al. Keeping up appearances , 2002, Annals of the rheumatic diseases.
[59] O. Meyer,et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. , 1999, The Journal of rheumatology.
[60] A. Marchesoni,et al. Cyclosporin A in the treatment of adult onset Still's disease. , 1997, The Journal of rheumatology.
[61] R. Priori,et al. Adult-onset Still's disease: not always so good. , 2012, Clinical and experimental rheumatology.
[62] 이종석,et al. Adult Onset Still`s Disease (AOSD) , 1999 .